A Randomized Phase 2 KINETIC Trial Evaluating SAGE-324/BIIB124 in Individuals with Essential Tremor

Keyphrases

• Randomized Phase II Trial 100%
• Essential Tremor 100%
• Placebo 80%
• Assessment Scale 40%
• Rating Assessment 40%
• Further Development 20%
• Phase II Study 20%
• Randomized Placebo-controlled Trial 20%
• Treatment-related Adverse Events 20%
• Once-daily 20%
• Somnolence 20%
• Movement Disorders 20%
• Change from Baseline 20%
• Dizziness 20%
• Sage 20%
• Least Mean Square 20%
• GABAA Receptor (GABAAR) 20%
• Upper Limb Tremor 20%
• Movement Disorder Society 20%
• Balance Disorders 20%
• Tremor Treatment 20%
• Positive Allosteric Modulator 20%
• Parkinson's Disorder 20%

Medicine and Dentistry

• Placebo 100%
• Essential Tremor 100%
• Stereotypic Movement Disorder 40%
• Adverse Event 20%
• Upper Limb 20%
• Dizziness 20%
• Somnolence 20%
• Limb Tremor 20%
• Balance Disorder 20%
• Allosteric Modulator 20%
• GABAA Receptor 20%
• Least Squares Method 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Essential Tremor 100%
• Motor Dysfunction 40%
• Adverse Event 20%
• Receptor 20%
• Somnolence 20%
• Dizziness 20%
• 4 Aminobutyric Acid 20%
• Positive Allosteric Modulator 20%
• Limb Tremor 20%
• Balance Disorder 20%